SFG
KRYS icon

Steward Financial Group’s Krystal Biotech KRYS Stock Holding History

Steward Financial Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$0 Buy
+3
New +$366 ﹤0.01% 1440

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Steward Financial Group's KRYS Position: Q3 2023 in Review

Steward Financial Group opened a new position in Krystal Biotech (KRYS) in Q3 2023: 3 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1440 among its holdings.

188 funds tracked by Wall St. Rank hold KRYS as of Q3 2023.

  • Steward Financial Group held 3 shares of Krystal Biotech worth $0 as of Q3 2023.
  • Krystal Biotech was a new Steward Financial Group position in Q3 2023.
  • Krystal Biotech made up ﹤0.01% of Steward Financial Group's portfolio in Q3 2023, its #1440 holding.
  • 188 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2023.

Based on Steward Financial Group's 13F filing for Q3 2023, filed 23 Oct 2023.